Wedbush Cuts Earnings Estimates for Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Wedbush dropped their Q1 2025 earnings per share estimates for Xenon Pharmaceuticals in a report released on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of ($0.87) per share for the quarter, down from their previous forecast of ($0.84). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.68) EPS, FY2026 earnings at ($4.23) EPS, FY2027 earnings at ($3.43) EPS and FY2028 earnings at $1.42 EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the firm posted ($0.73) EPS.

XENE has been the subject of several other reports. Raymond James reissued an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Trading Down 0.3 %

NASDAQ:XENE opened at $40.00 on Monday. The company has a 50-day moving average of $40.23 and a 200-day moving average of $40.82. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -14.18 and a beta of 1.20. Xenon Pharmaceuticals has a twelve month low of $35.53 and a twelve month high of $50.99.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of XENE. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 641 shares in the last quarter. Avior Wealth Management LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter worth approximately $101,000. nVerses Capital LLC acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth $102,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 487 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 780 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gary Patou sold 4,891 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the sale, the director now owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,383 shares of company stock valued at $2,535,891. Corporate insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.